FGF23 and hypophosphatemia: Given that elevated FGF23 in XLH is the cause of hypophosphatemia, with the latter being a major driver of osteomalacia and fractures in adults (10), neutralization of FGF23 with burosumab, and restoring serum phosphate levels, was anticipated to potentially reduce the risk of future fractures.